Abbott (ABT)

Executive Summary

Abbott Laboratories is a diversified healthcare leader operating across diagnostics, medical devices, nutrition, and established pharmaceuticals. With a market cap of ~$179B, the company generates robust revenue from core franchises such as FreeStyle Libre continuous glucose monitors (CGM), heart failure devices, and diagnostic tests. Abbott has consistently delivered mid-single-digit organic growth, supported by innovation and geographic expansion. Recent quarters have seen strong performance in diabetes care, with FreeStyle Libre exceeding $5B in annual sales, and steady recovery in diagnostics ex-COVID. The company maintains a high operating margin and strong free cash flow, enabling investment in new product launches and strategic acquisitions. Looking ahead, Abbott is well-positioned to capitalize on several high-growth opportunities. In diabetes, the FDA submission of FreeStyle Libre 3 (factory-calibrated, smaller sensor) and over-the-counter (OTC) Lingo biosensor could expand the addressable market. In cardiovascular, the AVEIR dual-chamber leadless pacemaker system is a game-changing innovation, while the TriClip transcatheter tricuspid valve repair system addresses a large unmet need. Additionally, Abbott’s diagnostics business is benefiting from new assays and point-of-care platforms. Regulatory approvals and Medicare coverage decisions for these products, combined with continued adoption of Libre and structural heart devices, underpin our conviction.

Upcoming Catalysts (preview)

• Q3 2026FDA approval of FreeStyle Libre 3 OTC biosensor (Lingo)85% success
• Q4 2026AVEIR dual-chamber leadless pacemaker FDA approval70% success
• Q1 2027TriClip label expansion to include moderate tricuspid regurgitation60% success